Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Destiny Pharma reports progress on clinical assets
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset. The AIM-traded firm said the product held substantial market potential for the company, with promising benefits for patients and healthcare systems.
To achieve that goal, Destiny said it was actively exploring various options, including ongoing discussions with potential partners.
Its objective was to secure the most advantageous deal to maximise shareholder value, with further updates to be provided in due course.
In addition to XF-73 Nasal, Destiny said it was looking ahead to advancing the NTCD-M3 development programme throughout 2024 in collaboration with Sebela Pharmaceuticals.
Pre-clinical results for XF-73 Dermal were expected imminently.
Additionally, the company anticipated making significant progress across its XF drug platform and assets, with established target indications for XF-73 Dermal and XF-70, a novel antifungal from the XF drug platform, later in 2024.
Destiny said it was funded through the first quarter of 2025.
"I am extremely excited by the potential of our products to reduce the emergence and impact of drug-resistant pathogens, and since arriving as CEO in September, I have been evaluating with the board the best way to realise their full value," said chief executive officer Chris Tovey.
"Having successfully completed a deal with Sebela Pharmaceuticals for NTCD-M3 during 2023, we're continuing to progress our partnering activities, and discussions with multiple interested parties are ongoing.
"The strengthened leadership team and board are completely focused on achieving the best deal that we can for XF-73 Nasal as we evaluate all the options that could deliver this product to patients and maximum value to shareholders."
At 1108 GMT, shares in Destiny Pharma were down 3.26% at 66.75p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.